Cingulate Inc. is a clinical-stage biopharmaceutical company based in Kansas City, specializing in the development of innovative therapies for neurobiological and central nervous system disorders. With a proprietary pipeline of drug candidates focused on addressing significant unmet needs in psychiatry and neurology, Cingulate aims to enhance therapeutic efficacy and improve mental health outcomes. The company's strategic initiatives reflect a strong commitment to advancing treatments for debilitating mental health conditions, which not only promise to benefit patients but also present valuable opportunities for investors and stakeholders alike. Show more
Location: 1901 WEST 47TH PLACE, KANSAS CITY, KS, UNITED STATES, 66205, Kansas City, KS, 66205, USA | Website: https://www.cingulate.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
42.74M
52 Wk Range
$3.20 - $6.74
Previous Close
$5.72
Open
$5.66
Volume
190,186
Day Range
$5.47 - $5.89
Enterprise Value
41.05M
Cash
6.119M
Avg Qtr Burn
-4.244M
Insider Ownership
1.39%
Institutional Own.
5.44%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
CTx-1301 (dexmethylphenidate) Details Attention deficit hyperactivity disorder | PDUFA Approval decision | |
CTx-1302 (dextroamphetamine) Details Attention deficit hyperactivity disorder | Phase 1/2 Initiation | |
CTx-2103 (buspirone) Details Anxiety Disorders | IND Submission |